Feedback / Questions
ulodesine (LR 09) - Laevoroc Oncology
https://www.globenewswire.com/news-release/2023/02/28/2616693/0/en/Laevoroc-Immunology-Announces-FDA-Orphan-Drug-Designation-Granted-to-LR-09-a-Novel-Metabolic-Immune-Checkpoint-Inhibitor-for-the-Treatment-of-Leukemia-Relapse-after-Allogeneic-Stem.html
Feb 28, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next